We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab.
- Authors
Vakiti, Anusha; Singh, Daulath; Pilla, Ravi; Alhaj-Moustafa, Muhamad; Fitzpatrick, Kelly W
- Abstract
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect. It encompasses the clinical triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure, without any association with Shiga toxins. Eculizumab is a terminal complement inhibitor used in the treatment of atypical hemolytic uremic syndrome. Herein, we present three cases of bevacizumab-induced atypical hemolytic syndrome treated successfully with eculizumab.
- Subjects
THERAPEUTIC use of monoclonal antibodies; HEMOLYTIC-uremic syndrome; TUMORS; BEVACIZUMAB
- Publication
Journal of Oncology Pharmacy Practice, 2019, Vol 25, Issue 4, p1011
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/1078155218774895